These similarities and the fact that VPAC2R activation has been associated to the side effects of PACAP through its periphery distribution (Fizanne et al., 2004), support the view that PAC1R activation seems to be the most approachable therapy in the field of neurodegenerative diseases. The gene discussed is VIPR2; the disease is neurodegenerative disease.